Oxford Biomedica PLC Bioverativ Collaboration and Licence Agreement (9382E)
February 15 2018 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 9382E
Oxford Biomedica PLC
15 February 2018
Oxford BioMedica Announces Collaboration and Licence Agreement
with Bioverativ in the Field of Haemophilia Gene Therapy
Oxford, UK- 15 February 2018: Oxford BioMedica plc (LSE:OXB)
("Oxford BioMedica" or "the Group"), a leading gene and cell
therapy group, today announces that it has completed a major new
collaboration & licence agreement with Bioverativ Inc. for the
development and manufacturing of lentiviral vectors to treat
haemophilia. The agreement includes a licence to use OXB's
LentiVector Enabled technology and access to its industrial-scale
manufacturing technology.
Under the terms of the agreement, Oxford BioMedica will receive
a $5 million upfront payment from Bioverativ. Oxford BioMedica is
also eligible to receive various milestone payments, potentially
worth in excess of $100 million, and undisclosed royalties on net
sales of Bioverativ's lentiviral vector haemophilia products.
Bioverativ will also fund process development and scale-up
activities for its lentiviral vector haemophilia products at Oxford
BioMedica. The agreement also allows for the parties to put in
place a clinical supply agreement for GMP manufacturing of
haemophilia products at Oxford BioMedica.
Commenting on the announcement, John Dawson, Chief Executive
Officer of Oxford BioMedica, said: "Today's news demonstrates the
value of our LentiVector Enabled platform and our leading
capabilities and reputation in the industrial scale-up for
lentiviral vectors for clinical and commercial supply. Bioverativ's
investment in haemophilia gene therapy underlines the potential of
lentiviral vectors for use for in vivo gene therapy. This new deal,
potentially worth in excess of $100m, demonstrates Oxford
BioMedica's strategy of building multiple partnerships with leaders
in their therapeutic categories and will support the Group's
continued growth. Oxford BioMedica is recognised as a world leader
in the field of development and manufacturing of lentiviral vectors
and we are delighted to be supporting Bioverativ in the development
of gene therapy products to treat haemophilia."
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Stuart Paynter, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Philippa Gardner/Laura
Thornton
Peel Hunt (Joint Corporate Tel: +44 (0)20 7418
Brokers): 8900
James Steel
Christopher Golden
WG Partners (Joint Corporate Tel: +44 (0)20 3705
Brokers): 9321
David Wilson
Claes Spang
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
Notes to editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and
ex-vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Bioverativ, GC
LabCell and Immune Design, through which it has long-term economic
interests in other potential gene and cell therapy products. Oxford
BioMedica is based across several locations in Oxfordshire, UK and
employs more than 300 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRDDGDDIXBBGIS
(END) Dow Jones Newswires
February 15, 2018 02:00 ET (07:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024